Biologics for Immune-Mediated Sensorineural Hearing Loss

Area of Science:

• Immunology
• Otolaryngology
• Genetics

Background:

• Immune-mediated hearing loss encompasses conditions like autoimmune inner ear disease, sudden sensorineural hearing loss, and Meniere's disease.
• Corticosteroids are the standard acute treatment, but effectiveness diminishes over time for many patients.
• Interleukin-1 (IL-1) is implicated in corticosteroid-resistant cases.

Purpose of the Study:

• To explore the role of interleukin-1 (IL-1) in immune-mediated sensorineural hearing loss.
• To investigate the potential therapeutic benefit of IL-1 inhibition in corticosteroid-resistant hearing loss.

Main Methods:

• Review of existing literature on immune-mediated hearing loss.
• Analysis of IL-1 expression in corticosteroid-resistant patients.
• Examination of IL-1 inhibition in autoinflammatory diseases with hearing loss.

Main Results:

• A significant portion of patients (60-70%) show initial response to corticosteroids, but this response is often transient.
• Elevated IL-1 expression is observed in patients with hearing loss resistant to corticosteroids.
• Autoinflammatory diseases, linked to innate immune dysregulation, present with sensorineural hearing loss and benefit from IL-1 inhibition.

Conclusions:

• Interleukin-1 (IL-1) plays a crucial role in the pathophysiology of immune-mediated sensorineural hearing loss.
• IL-1 inhibition presents a promising therapeutic strategy for patients with corticosteroid-resistant hearing loss.
• The findings strengthen the link between IL-1 dysregulation and immune-mediated hearing impairment.